目的探讨DRD2和DRD3基因多态性与利培酮治疗精神分裂症临床疗效间的关系.方法共106例中国西南地区汉族精神分裂症患者接受单一利培酮治疗12周,应用阴性和阳性症状量表(Positive and Negative Syndrome Scale,PANSS)、个人和社会功能量表...目的探讨DRD2和DRD3基因多态性与利培酮治疗精神分裂症临床疗效间的关系.方法共106例中国西南地区汉族精神分裂症患者接受单一利培酮治疗12周,应用阴性和阳性症状量表(Positive and Negative Syndrome Scale,PANSS)、个人和社会功能量表(Personal and Social Performance Scale,PSP)、瑞文标准推理测验、韦氏智能测验数字识记法、数字划消测验分别对患者进行基线和12周末的测评,同时收集同一地区汉族健康对照178例;采用Taq Man等位基因分型方法对DRD2和DRD3基因的3个多态性位点(rs1800496,rs6276,rs6280)进行基因分型,SHEsis在线软件来检测Hardy-Weinberg平衡、基因型和等位基因频率分析.采用SPSS17.0统计软件包进行统计分析.结果 (1)rs1800496对照组和实验组均为单一基因型AG,未见纯合子,不是基因多态性位点;(2)精神分裂症组与对照组在2个多态性位点的基因型分布和等位基因频率上均无统计学差异(P>0.05);(3)治疗前,DRD2基因rs6276三种基因型患者在基线PANSS阴性症状得分上的差异具有统计学意义(P=0.007).治疗后,DRD2基因rs6276三种基因型在治疗前后PANSS阴性症状得分差值(P=0.002)以及PSP总分差值上的差异具有统计学意义(P=0.024).结论利培酮治疗精神分裂症疗效显著,对部分认知功能有改善作用,DRD2基因的rs6276多态性可能与利培酮治疗精神分裂症阴性症状的改善有关系,DRD3基因的rs6280多态性可能与利培酮治疗精神分裂症的疗效无关.展开更多
目的比较阿立哌唑与利培酮治疗女性首发精神分裂症患者的疗效和血浆催乳素水平变化及其与多巴胺D3受体(DRD3)基因Ser9Gly(rs6280)多态性的关联。方法选择完成8周阿立哌唑或利培酮治疗的女性首发精神分裂症患者各60例,于治疗前和治疗8周...目的比较阿立哌唑与利培酮治疗女性首发精神分裂症患者的疗效和血浆催乳素水平变化及其与多巴胺D3受体(DRD3)基因Ser9Gly(rs6280)多态性的关联。方法选择完成8周阿立哌唑或利培酮治疗的女性首发精神分裂症患者各60例,于治疗前和治疗8周后分别评测阳性与阴性症状量表(positive and negativesymptom scale,PANSS)。采用放射免疫法检测血浆催乳素水平,DNA测序技术检测DRD3基因Ser9Gly多态性,分析DRD3基因Ser9Gly多态性与两药疗效及血浆催乳素变化的关联。结果治疗8周后,两组PANSS减分率的差异无统计学意义[(59.79±23.48)vs.(63.30±22.66),P>0.05],但利培酮组血浆催乳素的变化值高于阿立哌唑组[(26.92±9.48)vs.(-25.25±8.07),P<0.05]。利培酮组中C等位基因携带者的血浆催乳素的增加明显高于未携带者[(52.48±27.01)ng/mL vs(36.07±17.46),P<0.05];而阿立哌唑组中未见此差异[(-23.27±8.36)vs.TT(-26.05±8.11),P>0.05]。两组8周后PANSS减分率(%)与DRD3基因Ser9Gly的差异均无统计学意义:阿立哌唑组[CC+CT(57.83±19.94)vs.TT(56.84±18.46),P>0.05];利培酮组[CC+CT(53.94±21.08)vs.TT(60.38±19.37),P>0.05]。结论阿立哌唑治疗女性首发精神分裂症疗效与利培酮相当,但引起血浆催乳素水平变化的幅度较小;利培酮引起血浆催乳素水平增加可能与DRD3基因Ser9Gly多态性有关联。展开更多
目的系统评价DRD3基因Ser9Gly多态性与特发性震颤的相关性。方法计算机检索pubmed、Web of Science、中国知网(Chinese National Knowledge Infrastructure,CNKI)、维普数据库、中国生物医学文献数据库、万方数据库,收集2019年10月前有...目的系统评价DRD3基因Ser9Gly多态性与特发性震颤的相关性。方法计算机检索pubmed、Web of Science、中国知网(Chinese National Knowledge Infrastructure,CNKI)、维普数据库、中国生物医学文献数据库、万方数据库,收集2019年10月前有关DRD3基因Ser9Gly多态性与特发性震颤的病例-对照研究。应用统计学软件Stata14.0进行Meta分析。结果共纳入8项病例-对照研究,病例组1456例,对照组1651例。Meta分析结果显示,显性模型中GG+GA基因型的群体发病风险高于AA基因型的群体[OR=1.16,95%CI(1.00,1.35),P=0.043]。基于人种的亚组分析显示,DRD3基因Ser9Gly多态性与特发性震颤之间的相关性仅存在于高加索人群中。结论高加索人群中DRD3基因Ser9Gly多态性与特发性震颤具有相关性,且GG+GA基因型的存在增加发病风险。展开更多
[Objectives] This study aimed to study the distribution characteristics of DRD3(dopamine receptor-3) and the changes in its expression before and after spinal cord injury(SCI), in order to lay a morphological basis fo...[Objectives] This study aimed to study the distribution characteristics of DRD3(dopamine receptor-3) and the changes in its expression before and after spinal cord injury(SCI), in order to lay a morphological basis for later research. [Methods] Adult male Wistar rats were randomly divided into sham operation group and SCI group. The rat spinal cord transection model at the sacral 2(S_2) segment was established. Rat tail spasticity score was performed 60 d after SCI, and the rats with 4-5 points were screened for perfusion. The expression of DRD3 in the sacral spinal cord(S+C segment) was detected by immunofluorescence. [Results] In normal rats, DRD3 was mainly distributed in the dorsal horn(DH), intermediate zone(IMZ) and ventral horn(VH) of the gray matter. It was also expressed in the white matter of the spinal cord. After SCI, the distribution of DRD3 in the segment below the injury section was similar to that of normal rats. However, the expression was different(P<0.05). [Conclusions] There was no significant change in the distribution of DRD3 in spinal cord after SCI. After the spinal cord S_2 was completed transected, the expression of DRD3 was significantly reduced in the DH, IMZ and VH regions of the gray matter of the spinal cord.展开更多
文摘目的探讨DRD2和DRD3基因多态性与利培酮治疗精神分裂症临床疗效间的关系.方法共106例中国西南地区汉族精神分裂症患者接受单一利培酮治疗12周,应用阴性和阳性症状量表(Positive and Negative Syndrome Scale,PANSS)、个人和社会功能量表(Personal and Social Performance Scale,PSP)、瑞文标准推理测验、韦氏智能测验数字识记法、数字划消测验分别对患者进行基线和12周末的测评,同时收集同一地区汉族健康对照178例;采用Taq Man等位基因分型方法对DRD2和DRD3基因的3个多态性位点(rs1800496,rs6276,rs6280)进行基因分型,SHEsis在线软件来检测Hardy-Weinberg平衡、基因型和等位基因频率分析.采用SPSS17.0统计软件包进行统计分析.结果 (1)rs1800496对照组和实验组均为单一基因型AG,未见纯合子,不是基因多态性位点;(2)精神分裂症组与对照组在2个多态性位点的基因型分布和等位基因频率上均无统计学差异(P>0.05);(3)治疗前,DRD2基因rs6276三种基因型患者在基线PANSS阴性症状得分上的差异具有统计学意义(P=0.007).治疗后,DRD2基因rs6276三种基因型在治疗前后PANSS阴性症状得分差值(P=0.002)以及PSP总分差值上的差异具有统计学意义(P=0.024).结论利培酮治疗精神分裂症疗效显著,对部分认知功能有改善作用,DRD2基因的rs6276多态性可能与利培酮治疗精神分裂症阴性症状的改善有关系,DRD3基因的rs6280多态性可能与利培酮治疗精神分裂症的疗效无关.
文摘目的比较阿立哌唑与利培酮治疗女性首发精神分裂症患者的疗效和血浆催乳素水平变化及其与多巴胺D3受体(DRD3)基因Ser9Gly(rs6280)多态性的关联。方法选择完成8周阿立哌唑或利培酮治疗的女性首发精神分裂症患者各60例,于治疗前和治疗8周后分别评测阳性与阴性症状量表(positive and negativesymptom scale,PANSS)。采用放射免疫法检测血浆催乳素水平,DNA测序技术检测DRD3基因Ser9Gly多态性,分析DRD3基因Ser9Gly多态性与两药疗效及血浆催乳素变化的关联。结果治疗8周后,两组PANSS减分率的差异无统计学意义[(59.79±23.48)vs.(63.30±22.66),P>0.05],但利培酮组血浆催乳素的变化值高于阿立哌唑组[(26.92±9.48)vs.(-25.25±8.07),P<0.05]。利培酮组中C等位基因携带者的血浆催乳素的增加明显高于未携带者[(52.48±27.01)ng/mL vs(36.07±17.46),P<0.05];而阿立哌唑组中未见此差异[(-23.27±8.36)vs.TT(-26.05±8.11),P>0.05]。两组8周后PANSS减分率(%)与DRD3基因Ser9Gly的差异均无统计学意义:阿立哌唑组[CC+CT(57.83±19.94)vs.TT(56.84±18.46),P>0.05];利培酮组[CC+CT(53.94±21.08)vs.TT(60.38±19.37),P>0.05]。结论阿立哌唑治疗女性首发精神分裂症疗效与利培酮相当,但引起血浆催乳素水平变化的幅度较小;利培酮引起血浆催乳素水平增加可能与DRD3基因Ser9Gly多态性有关联。
文摘目的系统评价DRD3基因Ser9Gly多态性与特发性震颤的相关性。方法计算机检索pubmed、Web of Science、中国知网(Chinese National Knowledge Infrastructure,CNKI)、维普数据库、中国生物医学文献数据库、万方数据库,收集2019年10月前有关DRD3基因Ser9Gly多态性与特发性震颤的病例-对照研究。应用统计学软件Stata14.0进行Meta分析。结果共纳入8项病例-对照研究,病例组1456例,对照组1651例。Meta分析结果显示,显性模型中GG+GA基因型的群体发病风险高于AA基因型的群体[OR=1.16,95%CI(1.00,1.35),P=0.043]。基于人种的亚组分析显示,DRD3基因Ser9Gly多态性与特发性震颤之间的相关性仅存在于高加索人群中。结论高加索人群中DRD3基因Ser9Gly多态性与特发性震颤具有相关性,且GG+GA基因型的存在增加发病风险。
基金Sponsored by National Natural Science Foundation of China(81501080)Key Project of Education Department of Hebei Province(GD2015002)
文摘[Objectives] This study aimed to study the distribution characteristics of DRD3(dopamine receptor-3) and the changes in its expression before and after spinal cord injury(SCI), in order to lay a morphological basis for later research. [Methods] Adult male Wistar rats were randomly divided into sham operation group and SCI group. The rat spinal cord transection model at the sacral 2(S_2) segment was established. Rat tail spasticity score was performed 60 d after SCI, and the rats with 4-5 points were screened for perfusion. The expression of DRD3 in the sacral spinal cord(S+C segment) was detected by immunofluorescence. [Results] In normal rats, DRD3 was mainly distributed in the dorsal horn(DH), intermediate zone(IMZ) and ventral horn(VH) of the gray matter. It was also expressed in the white matter of the spinal cord. After SCI, the distribution of DRD3 in the segment below the injury section was similar to that of normal rats. However, the expression was different(P<0.05). [Conclusions] There was no significant change in the distribution of DRD3 in spinal cord after SCI. After the spinal cord S_2 was completed transected, the expression of DRD3 was significantly reduced in the DH, IMZ and VH regions of the gray matter of the spinal cord.
